Laurence Terrisse Rulleau, PhD, served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. She worked at different firms including Desjardins securities, Yorkton securities and Blackmont securities. In her experience as an analyst, she researched over 100 life sciences companies with scientific due diligence on these companies as well as market analysis and competition assessment.
Dr. Rulleau was ranked the number one Canadian life sciences analyst by the Starmine survey (a Thomson Reuters Company) and number one independent analyst by Brendon Wood survey. She was involved in numerous mergers and acquisitions as well as IPOs. Dr. Rulleau was also CEO of HLA-G Technologies, a biotechnology start-up based in France, and more recently, she served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor in the last three years, more than 40 licences with the industry were signed and eight companies started.
Dr. Rulleau has a Masters in Biology from The Université du Québec à Montréal (UQAM) and a PhD from Montreal University executed at Montreal Clinical Research Institute.